IBB:NSD-iShares Nasdaq Biotechnology Index Fund (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 137.22

Change

-0.57 (-0.41)%

Market Cap

USD 8.53B

Volume

1.44M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ? listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Inception Date: 05/02/2001

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.47%

Management Expense Ratio: 0.47 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF 0.36 %

N/A

USD 0.49B
BBH VanEck Biotech ETF 0.35 %

N/A

USD 0.41B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

N/A

USD 0.20B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

N/A

USD 0.13B
GNOM Global X Genomics & Biotechnol.. 0.00 %

N/A

USD 0.09B
BTEC Principal Healthcare Innovator.. 0.42 %

N/A

USD 0.04B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

N/A

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

N/A

USD 0.02B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Horizons Seasonal Rotatio.. 0.00 % 1.27 %

N/A

CAD 0.21B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.01% 33% F 52% F
Dividend Return 0.09% 67% D+ 3% F
Total Return 1.10% 33% F 50% F
Trailing 12 Months  
Capital Gain 7.85% 44% F 62% D
Dividend Return 0.32% 40% F 2% F
Total Return 8.17% 44% F 59% D-
Trailing 5 Years  
Capital Gain 22.74% 50% F 64% D
Dividend Return 1.38% 29% F 5% F
Total Return 24.12% 50% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.88% 56% F 65% D
Dividend Return 6.10% 56% F 62% D
Total Return 0.22% 38% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.91% 67% D+ 75% C
Risk Adjusted Return 29.16% 56% F 66% D+
Market Capitalization 8.53B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.